NASDAQ:PRLD Prelude Therapeutics (PRLD) Stock Price, News & Analysis $1.64 -0.12 (-6.82%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Prelude Therapeutics Stock (NASDAQ:PRLD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Prelude Therapeutics alerts:Sign Up Key Stats Today's Range$1.58▼$1.7650-Day Range$1.76▼$5.8752-Week Range$1.58▼$6.80Volume327,979 shsAverage Volume139,187 shsMarket Capitalization$90.23 millionP/E RatioN/ADividend YieldN/APrice Target$4.75Consensus RatingHold Company OverviewPrelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Prelude Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks64th Percentile Overall ScorePRLD MarketRank™: Prelude Therapeutics scored higher than 64% of companies evaluated by MarketBeat, and ranked 387th out of 1,001 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingPrelude Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, no hold ratings, and 2 sell ratings.Amount of Analyst CoveragePrelude Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Prelude Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Prelude Therapeutics are expected to grow in the coming year, from ($1.85) to ($1.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prelude Therapeutics is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prelude Therapeutics is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrelude Therapeutics has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Prelude Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.73% of the float of Prelude Therapeutics has been sold short.Short Interest Ratio / Days to CoverPrelude Therapeutics has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Prelude Therapeutics has recently decreased by 25.23%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPrelude Therapeutics does not currently pay a dividend.Dividend GrowthPrelude Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.73% of the float of Prelude Therapeutics has been sold short.Short Interest Ratio / Days to CoverPrelude Therapeutics has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Prelude Therapeutics has recently decreased by 25.23%, indicating that investor sentiment is improving significantly. News and Social MediaN/ANews SentimentN/A Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Prelude Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders62.80% of the stock of Prelude Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.72% of the stock of Prelude Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Prelude Therapeutics' insider trading history. Receive PRLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PRLD Stock News HeadlinesPrelude Therapeutics Showcases Innovative SMARCA Degrader Programs at Barcelona SymposiumOctober 10, 2024 | msn.comPrelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR SymposiumOctober 9, 2024 | globenewswire.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)Prelude Therapeutics (NASDAQ:PRLD) Stock Quotes, Forecast and News SummaryOctober 1, 2024 | benzinga.comHC Wainwright & Co. Upgrades Prelude Therapeutics (PRLD)September 20, 2024 | msn.comPrelude Therapeutics (PRLD) Gets a Sell from BarclaysSeptember 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Prelude Therapeutics on Promising PRT3789 Trial Results and Strong Financial PositionSeptember 16, 2024 | markets.businessinsider.comPrelude Therapeutics Releases Promising Phase 1 Data on Novel Cancer TreatmentSeptember 16, 2024 | msn.comSee More Headlines PRLD Stock Analysis - Frequently Asked Questions How have PRLD shares performed this year? Prelude Therapeutics' stock was trading at $4.27 at the beginning of 2024. Since then, PRLD stock has decreased by 61.6% and is now trading at $1.64. View the best growth stocks for 2024 here. How were Prelude Therapeutics' earnings last quarter? Prelude Therapeutics Incorporated (NASDAQ:PRLD) announced its quarterly earnings results on Monday, August, 12th. The company reported ($0.46) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.46). When did Prelude Therapeutics IPO? Prelude Therapeutics (PRLD) raised $149 million in an initial public offering on Friday, September 25th 2020. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities acted as the underwriters for the IPO. Who are Prelude Therapeutics' major shareholders? Top institutional investors of Prelude Therapeutics include Exchange Traded Concepts LLC (0.15%). Insiders that own company stock include Orbimed Advisors Llc, Krishna Vaddi, Laurent Chardonnet, Andrew Combs and Deborah Morosini. View institutional ownership trends. How do I buy shares of Prelude Therapeutics? Shares of PRLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Prelude Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prelude Therapeutics investors own include Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Visa (V) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/12/2024Today10/23/2024Next Earnings (Estimated)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PRLD CUSIPN/A CIK1678660 Webwww.preludetx.com Phone302-467-1280FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$4.75 High Stock Price Target$7.00 Low Stock Price Target$3.00 Potential Upside/Downside+189.6%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-121,830,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-59.82% Return on Assets-51.55% Debt Debt-to-Equity RatioN/A Current Ratio7.83 Quick Ratio7.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.32 per share Price / Book0.38Miscellaneous Outstanding Shares55,020,000Free Float20,469,000Market Cap$90.23 million OptionableOptionable Beta1.48 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report This page (NASDAQ:PRLD) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.